ISNES, Belgium, Sept. 5, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced that its Chief Executive Officer, Cameron Reynolds and/or its Executive Vice President of Investor Relations, Scott Powell, are scheduled to attend and present at multiple conferences in September.
During their presentations, management will outline Volition's business, clinical, regulatory and operational milestones.
Details of the conferences are as follows:
Conference: Share Investor Event
Date: Wednesday, September 12, 2018
Time: 5:00 p.m. GMT
Location: Radisson Blu Hotel, Edinburgh
Conference: 19th Annual GCFF Toronto Conference 2018
Date: Saturday, September 15, 2018
Time: 9:00 a.m. – 5:00 p.m. ET
Location: Toronto Marriott Markham, Markham, ON
Conference: Sidoti & Company Fall 2018 Conference
Date: Thursday, September 27, 2018
Time: 8:00 a.m. – 5:00 p.m. ET
Location: NYC Grand Hyatt Hotel, New York, NY
Conference: MicroCap Leadership Summit
Date: Friday September 28, 2018
Time: 8:30 a.m. – 5:00 p.m. CDT (Small Group Presentations)
Location: Westin Chicago Northwest Hotel, Itasca, IL
Persons attending any of the above-referenced conferences who would like to schedule a 1-on-1 meeting with Volition management during such conference may do so by contacting Joseph Green of Edison Advisors at JGreen@edisongroup.com or Scott Powell, Executive Vice President of Investor Relations, at email@example.com.
Volition is a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers. The tests are based on the technology platform of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.
As cancer screening programs become more widespread, Volition's products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.
Volition intends to expand the application of its technology beyond cancer by exploring other disease applications. The company's research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as it focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.
For more information about Volition, visit Volition's website https://volitionrx.com/ or connect with us via:
The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.
Louise Day, Chief Marketing & Communications Officer
+44 (0)7557 774620
Scott Powell, Executive Vice President, Investor Relations
+1 (646) 650 1351
Joseph Green, Edison Advisors
+1 (646) 653 7030
Nucleosomics®, NuQ®, Nu.QTM and Hypergenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
SOURCE VolitionRx Ltd
Released September 5, 2018